Pds biotech announces presentation of efficacy and safety data from versatile-002 phase 2 clinical trial in recurrent or metastatic head and neck cancer at asco 2022

Preliminary data from first 19 patients treated with pds0101 in combination with keytruda ® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck cancer, in comparison to the published results of approximately 19% for approved checkpoint inhibitors used as monotherapy for recurrent or metastatic head and neck cancer*
PDSB Ratings Summary
PDSB Quant Ranking